Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2024-04-10 Ascelia Pharma Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024 Pressreleaser Ladda ner | Visa Stäng
2024-04-10 Ascelia Pharma Ascelia Pharma rapporterar att SPARKLE-bildläsningsfasen är avslutad och förväntar sig headline-resultat i första halvan av maj 2024 Pressreleaser Ladda ner | Visa Stäng
2024-04-08 Ascelia Pharma Årsredovisning 2023: Solida framsteg med slutförd patientrekrytering till Orviglance fas 3 och förväntat headline-resultat i maj 2024 Rapporter Ladda ner | Visa Stäng
2024-04-08 Ascelia Pharma Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024 Rapporter Ladda ner | Visa Stäng
2024-03-27 Ascelia Pharma Notice of Annual General Meeting in Ascelia Pharma AB Pressreleaser Ladda ner | Visa Stäng
2024-03-27 Ascelia Pharma Kallelse till årsstämma i Ascelia Pharma AB Pressreleaser Ladda ner | Visa Stäng
2024-02-21 Penser Access by Carnegie Penser Access by Carnegie: Interview with Ascelia Pharma - Carnegie Investment Bank - Feb 21th 2024 Pressreleaser Visa Stäng
2024-02-12 Penser Access by Carnegie Penser Access by Carnegie: Ascelia Pharma - Finansiering på plats, avgörande data i maj Pressreleaser Visa Stäng
2024-02-12 Redeye Redeye: Ascelia Pharma Q4 2023 - On track with easing financial pressure Pressreleaser Ladda ner | Visa Stäng
2024-02-09 Ascelia Pharma Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May Rapporter Ladda ner | Visa Stäng
2024-02-09 Ascelia Pharma Q4 och bokslutskommuniké 2023: Stärkt finansiell position inför headline-resultat i maj för den kliniska fas-3 studien SPARKLE Rapporter Ladda ner | Visa Stäng
2024-02-04 Ascelia Pharma Ascelia Pharma säkrar finansiering om upp till 35 MSEK Pressreleaser Ladda ner | Visa Stäng
2024-02-04 Ascelia Pharma Ascelia Pharma Secures Financing of up to SEK 35 Million Pressreleaser Ladda ner | Visa Stäng
2024-01-24 Ascelia Pharma Orviglance Review Article Published in Investigative Radiology Pressreleaser Ladda ner | Visa Stäng
2024-01-24 Ascelia Pharma Översiktsartikel om Orviglance publicerad i Investigative Radiology Pressreleaser Ladda ner | Visa Stäng
2024-01-24 Ascelia Pharma Nomination Committee Appointed for AGM 2024 in Ascelia Pharma AB Pressreleaser Ladda ner | Visa Stäng
2024-01-24 Ascelia Pharma Valberedning utsedd i Ascelia Pharma AB inför årsstämman 2024 Pressreleaser Ladda ner | Visa Stäng
2023-12-07 Ascelia Pharma Ascelia Pharma Announces Start of Image Reading Phase and Re-confirms Phase 3 SPARKLE Results by May 2024 Pressreleaser Ladda ner | Visa Stäng
2023-12-07 Ascelia Pharma Ascelia Pharma meddelar start av bildläsningsfasen och bekräftar resultat från fas 3 SPARKLE senast i maj 2024 Pressreleaser Ladda ner | Visa Stäng
2023-12-06 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Ascelia Pharma AB Pressreleaser Visa Stäng
2023-11-30 Ascelia Pharma Change in Number of Shares and Votes in Ascelia Pharma AB Pressreleaser Ladda ner | Visa Stäng
2023-11-30 Ascelia Pharma Ändring av antalet aktier och röster i Ascelia Pharma AB Pressreleaser Ladda ner | Visa Stäng
2023-11-13 Ascelia Pharma Kommuniké från extra bolagsstämma den 13 november 2023 i Ascelia Pharma AB Pressreleaser Ladda ner | Visa Stäng
2023-11-13 Ascelia Pharma Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 13 November 2023 Pressreleaser Ladda ner | Visa Stäng
2023-11-09 Ascelia Pharma Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program Pressreleaser Ladda ner | Visa Stäng
2023-11-09 Ascelia Pharma Ascelia Pharma beslutar om omvandling av C-aktier till stamaktier för leverans till deltagare i incitaments-program Pressreleaser Ladda ner | Visa Stäng
2023-11-09 Penser Access Penser Access: Blickarna mot maj - Ascelia Pharma Pressreleaser Visa Stäng
2023-11-09 Redeye Redeye: Ascelia Q3 update - On track for a SPARKLE result in May 2024 Pressreleaser Ladda ner | Visa Stäng
2023-11-08 Ascelia Pharma QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan Rapporter Ladda ner | Visa Stäng
2023-11-08 Ascelia Pharma KVARTALSRAPPORT Q3 2022: Den ny utläsning av bilderna från fas 3-studien SPARKLE fortskrider enligt planen Rapporter Ladda ner | Visa Stäng
2023-10-19 Ascelia Pharma NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB Pressreleaser Ladda ner | Visa Stäng
2023-10-19 Ascelia Pharma KALLELSE TILL EXTRA BOLAGSSTÄMMA I ASCELIA PHARMA AB Pressreleaser Ladda ner | Visa Stäng
2023-10-04 Ascelia Pharma Ascelia Pharma får översiktsartikel om Orviglance accepterad för publicering i Investigative Radiology Pressreleaser Ladda ner | Visa Stäng
2023-10-04 Ascelia Pharma Ascelia Pharma Gets Acceptance for Publication of Orviglance Review Article in Investigative Radiology Pressreleaser Ladda ner | Visa Stäng
2023-09-18 Redeye Redeye: Ascelia Pharma - All attention on the top priority Pressreleaser Ladda ner | Visa Stäng
2023-09-13 Ascelia Pharma Ascelia Pharma to Reach Headline Results from SPARKLE Re-Evaluation by May 2024 with Current Funding Pressreleaser Ladda ner | Visa Stäng
2023-09-13 Ascelia Pharma Ascelia Pharma når headline-resultat från SPARKLE-utläsningen i maj 2024 med nuvarande finansiering Pressreleaser Ladda ner | Visa Stäng
2023-08-31 Ascelia Pharma Ascelia Pharma gör omfattande neddragning av organisationen för att nå headline-resultat med SPARKLE Pressreleaser Ladda ner | Visa Stäng
2023-08-31 Ascelia Pharma Ascelia Pharma significantly reduces organization to reach SPARKLE headline results Pressreleaser Ladda ner | Visa Stäng
2023-08-21 Penser Access Penser Access: I väntan på nästa milstolpe - Ascelia Pharma Pressreleaser Visa Stäng
2023-08-18 Ascelia Pharma Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE Rapporter Ladda ner | Visa Stäng
2023-08-18 Ascelia Pharma Halvårsrapport 2023: Ny utläsning krävs efter intraläsarinkonsistens rörande poängsättning av bilder av läsare från fas 3-studien SPARKLE Rapporter Ladda ner | Visa Stäng
2023-08-09 Ascelia Pharma Ascelia Pharma provides clarifications around the intra-reader variability in read-out of images in the SPARKLE study Pressreleaser Ladda ner | Visa Stäng
2023-08-09 Ascelia Pharma Ascelia Pharma ger förtydliganden kring intraläsarvariabilitet vid utläsningen av bilder i SPARKLE-studien Pressreleaser Ladda ner | Visa Stäng
2023-08-09 Penser Access Penser Access: Oväntat utfall - Ascelia Pharma Pressreleaser Visa Stäng
2023-08-09 Redeye Redeye: Ascelia Pharma - SPARKLE is blurred Pressreleaser Ladda ner | Visa Stäng
2023-08-07 Ascelia Pharma Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE Pressreleaser Ladda ner | Visa Stäng
2023-08-07 Ascelia Pharma Ny utläsning krävs efter intraläsarinkonsistens rörande poängsättning av bilder av läsare från fas 3-studien SPARKLE Pressreleaser Ladda ner | Visa Stäng
2023-06-20 Penser Access Penser Access: Sanningens ögonblick - Ascelia Pharma Pressreleaser Visa Stäng
2023-06-16 Ascelia Pharma Ascelia Pharma presented Orviglance Hepatic Impairment Data and hosted a Q&A with liver imaging experts at the 2023 ESGAR Annual Meeting Pressreleaser Ladda ner | Visa Stäng
2023-06-16 Ascelia Pharma Vid ESGARs årsmöte 2023 presenterade Ascelia Pharma Orviglance-data från studien med nedsatt leverfunktion samt var värd för en Q&A med experter inom leveravbildning Pressreleaser Ladda ner | Visa Stäng
2023-05-15 Redeye Redeye: Ascelia Pharma - SPARKLE is about to sparkle Pressreleaser Ladda ner | Visa Stäng
2023-05-12 Penser Access Penser Access: Nyckelhändelse stundar - Ascelia Pharma Pressreleaser Visa Stäng
2023-05-11 Ascelia Pharma KVARTALSRAPPORT Q1 2023: Fas 3 studien för Orviglance, SPARKLE, sista patientens sista besök (Last Patient Last Visit, LPLV) har avslutats Rapporter Ladda ner | Visa Stäng
2023-05-11 Ascelia Pharma QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed Rapporter Ladda ner | Visa Stäng
2023-05-04 Ascelia Pharma Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2023 Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 4 May 2023 | Ascelia Pharma

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2023

Today, on 4 May 2023, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.

Resolution on adoption of accounts and allocation of the company’s result
The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. The annual general meeting also resolved in accordance with the proposal from the board of directors to allocate the company’s result, meaning that no dividends are paid to the shareholders and that available funds of SEK 180,110,584 are carried forward.

Discharge from liability for the members of the board members and the CEO
The annual general meeting resolved to discharge the board members and the CEO from liability for the financial year 2022.

Election and remuneration of the board of directors and auditors
The annual general meeting resolved in accordance with the proposal from the Nomination Committee to re-elect Peter Benson, Niels Mengel, Helena Wennerström, Hans Maier and Lauren Barnes as board members. Peter Benson was re-elected as chairman of the board.

Furthermore, the annual general meeting resolved that remuneration to the board of directors shall be paid with SEK 525,000 to the chairman of the board and with SEK 262,500 to each of the other board members who are not employed by the company. It was further resolved that remuneration for committee work shall be paid with SEK 100,000 to the chairman of the Audit Committee, with SEK 25,000 to each of the other members of the Audit Committee, with SEK 100,000 to the chairman of the Commercialization Committee, with SEK 25,000 to each of the other members of the Commercialization Committee, with SEK 50,000 to the chairman of the Remuneration Committee and with SEK 25,000 to each of the other members of the Remuneration Committee. Furthermore, it was resolved that board members residing outside of Europe shall be paid additional board remuneration with SEK 10,000 per physical board meeting attended.

Finally, the annual general meeting resolved to re-elect Öhrlings PricewaterhouseCoopers AB as auditor and that remuneration to the auditor shall be paid in accordance with customary norms and approved invoice. Öhrlings PricewaterhouseCoopers AB has informed that the authorized public accountant Carl Fogelberg will continue to be the auditor in charge.

Resolution on remuneration of the Nomination Committee for work ahead of the annual general meeting in 2024
The annual general meeting resolved in accordance with the proposal from the Nomination Committee that remuneration shall be paid with SEK 50,000 to the chairman of the Nomination Committee for the work up and until the annual general meeting to be held in 2024.

Resolution on approval of remuneration report
The annual general meeting resolved to approve the board of directors’ remuneration report for the financial year 2022.

Resolution on authorization for the board of directors regarding issues
The annual general meeting resolved in accordance with the proposal from the board of directors to authorize the board of directors to, at one or several occasions, during the time up until the next annual general meeting, with or without deviation from the shareholders’ preferential rights, and with or without provisions regarding payment in kind or through set-off or other provisions, to resolve to issue new ordinary shares, convertibles and/or warrants. The reason for that deviation from the shareholders’ preferential rights shall be permitted is to enable the company to raise working capital, to execute acquisitions of companies or operating assets as well as to enable issues to industrial partners within the framework of partnerships and alliances. The total number of ordinary shares that that may be issued pursuant to the authorization (alternatively be issued through conversion of convertibles and/or exercise of warrants) shall be limited to a number that leads to a maximum dilution of 20 per cent (calculated after full utilization of the now proposed authorizations) of the total number of ordinary shares outstanding in the company at the time of the first issue resolution pursuant to the authorization. To the extent an issue is made with deviation from the shareholders’ preferential rights, the issue should be made on market terms.

Resolution on implementation of a long-term incentive program by way of (A) implementation of a performance-based share saving program; (B) authorization on directed issues of series C shares; (C) authorization for repurchase of series C shares; and (D) resolution on transfer of own ordinary shares
The annual general meeting resolved in accordance with the proposal from the board of directors to implement a long-term incentive program in the form of a performance-based share saving program (the “ LTI 2023 ”) for employees. LTI 2023 means that the participants will invest in or allocate already owned ordinary shares in the company (” Saving Shares ”). Following a predefined time period, the participants will, free of charge, have the right to receive additional shares in the company (“ Matching Shares ”). In addition, conditional upon fulfilment of a goal related to the development of the share price, the participants will further, free of charge, have the right to receive additional shares in the company (“ Performance Shares ”).

The maximum number of shares that can be issued in relation to LTI 2023 is 1,743,752, whereof 1,416,000 for delivery of Matching Shares and Performance Shares to the participants and in the aggregate 327,752 related to hedging of cash flow for social security payments, which corresponds to a dilution of approximately 4.92 per cent of the company’s ordinary shares after full dilution, calculated on the number of ordinary shares that will be added upon full issuance of shares in connection with LTI 2023.

In order to secure the company’s delivery of Matching Shares and Performance Shares to the participants under LTI 2023, the annual general meeting also resolved (i) to authorize the board of directors to resolve on directed issues of series C shares, whereby the new shares, with deviation from the shareholders’ preferential rights, only may be subscribed for by a bank or a securities company at a subscription price which corresponds to the quota value of the shares; (ii) to authorize the board of directors to resolve to repurchase own series C shares; and (iii) to approve transfer of own ordinary shares to the participants under LTI 2023.

Resolution on authorization for the board of directors regarding transfer of own ordinary shares
The annual general meeting resolved in accordance with the proposal from the board of directors to authorize the board of directors to, for the period up until the next annual general meeting, re-solve on transfer of not more than 44 664 own ordinary shares, for the purpose of hedging cash flow for social security payments that may occur in relation to LTI 2020. Transfer of shares shall be effected on Nasdaq Stockholm at a price within the, at each time, prevailing price interval for the share. The number of shares that may be transferred shall be subject to recalculation in conse-quence of an intervening bonus issue, split or reverse split, rights issue, and/or other similar corpo-rate actions which affects the number of shares in the company.

2023-05-04 Ascelia Pharma Kommuniké från årsstämma den 4 maj 2023 i Ascelia Pharma AB Pressreleaser Ladda ner | Visa Stäng
2023-04-25 Ascelia Pharma Studie av nedsatt leverfunktion (Hepatic Impairment Study) accepterad för presentation vid större radiologi- och leverkonferenser Pressreleaser Ladda ner | Visa Stäng
2023-04-25 Ascelia Pharma Hepatic Impairment Study Accepted for Presentation at Major Radiology and Liver Conferences Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

6 May 2024 | Årsstämma 2023
7 May 2024 | Årligutdelning
16 May 2024 | Kvartalsrapport 2024-Q1
15 Aug 2024 | Kvartalsrapport 2024-Q2
7 Nov 2024 | Kvartalsrapport 2024-Q3
7 Feb 2025 | Bokslutskommuniké 2024